LearnGlossaryMarketStocksSuperinvestorsSign in

MESO

Mesoblast Limited

Healthcare · $1.9B market cap

Verdict

We can't put a fair value on MESO right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-4.6% a year✗
Sales growth-9.4% a year✗
Free cash flow growth—?
Return on invested capital-11.0%✗

Follow MESO

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

None of the investors we track holds MESO right now. In Q1 2026, 1 sold out. Who we track

Moves in Q1 2026

Sold out: Polen Capital Management

About Mesoblast Limited

Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works